What are the most commonly reported RU58841 side effects?

Local ones: scalp irritation, dryness, itching and flaking, much of it attributable to the ethanol-based vehicle rather than the molecule. Systemically, a minority of heavy users report fatigue, low mood or libido changes; these reports are anecdotal, uncontrolled, and impossible to attribute cleanly, but they recur often enough to take seriously.

Is RU58841 safer than finasteride?

Unknowable with current evidence, and be wary of anyone who answers confidently in either direction. Finasteride has decades of controlled human data, including its side-effect profile. RU-58841 has no completed human trials at all. An absence of documented side effects is not the same as an absence of side effects.

Does RU58841 affect hormone levels?

By design it should not. It blocks the androgen receptor locally rather than lowering DHT production. The animal pharmacology supported limited systemic antiandrogenic effect at topical doses. But no human endocrine study exists, so 'should not' is the strongest honest phrasing.

Is RU58841 shedding normal?

An early shed in the first weeks is a common anecdotal report and is mechanistically plausible (follicles re-entering the growth phase release resting-phase hairs first). It has never been characterised in a controlled human study.

Does the vehicle matter for side effects?

Substantially. High-ethanol vehicles dry and irritate the scalp on their own, and a badly chosen vehicle changes how much compound penetrates. A 70/30 ethanol/propylene-glycol vehicle is the community-standard compromise between solubility, drying time and skin tolerance. It is what we use.

RU58841 Side Effects - What Research & Reports Actually Show

The short version

There is no controlled human side-effect data for RU-58841. That is the single most important fact on this page.
Commonly reported: local irritation (much of it the ethanol vehicle), and in a minority of heavy users, systemic-feeling effects.
The 1990s animal work reported limited systemic antiandrogenic activity at topical doses. Supportive, not proof.
Early shedding is commonly reported and mechanistically plausible; never formally studied.
Research use only. Nothing here is medical advice.

Start from the honest baseline

RU-58841 never completed human clinical trials, so there is no adverse-event table, no incidence percentages, no controlled comparison against placebo. Every side-effect claim you read about this molecule, including reassuring ones, is built from animal pharmacology, mechanism, and twenty years of self-reports. That evidence is worth reading carefully. It is not worth mistaking for a safety profile.

Local effects: the common ones

The most consistently reported effects are exactly where the solution goes: scalp irritation, dryness, itching and flaking. A large share of this is the vehicle, not the molecule. RU-58841 needs a high-ethanol carrier to stay dissolved at 5%, and concentrated ethanol strips and dries skin on its own. Redness or stinging on broken or freshly shaved skin is likewise vehicle-typical. Reports scale with application amount and frequency, which is what you would expect from a solvent effect.

The systemic question

This is the question that matters, and the one with the least data. The molecule was designed for local action: Battmann's 1994 pharmacology work reported strong topical antiandrogenic effects with limited systemic antiandrogenic activity in animal models, and that profile is the whole reason the compound was developed for skin conditions rather than prostate cancer.

Against that sit two honest complications. First, no human pharmacokinetic study has ever been published. Nobody has measured how much RU-58841 (or its metabolites) reaches human circulation from a scalp dose. Second, a minority of community users, typically at heavier use, report fatigue, mood changes, or reduced libido, the classic systemic-antiandrogen signature. These reports are uncontrolled, confounded (many users run several compounds at once), and rare relative to the size of the user base. They are also persistent enough across two decades that dismissing them outright would be dishonest. The correct summary: systemic exposure is an unquantified variable that likely depends on dose, vehicle, and skin condition.

Shedding

An early shed in the first weeks of use is one of the most common community reports, and it has a plausible mechanism: interventions that push miniaturised follicles back toward the anagen (growth) phase first release the club hairs sitting in telogen (rest). The same phenomenon is well documented for minoxidil in controlled settings. For RU-58841 specifically, it exists only as anecdote: consistent, plausible anecdote, but anecdote.

What the animal studies did and didn't show

The published animal work (the rodent pharmacology and the stump-tailed macaque studies) was efficacy- and mechanism-focused. It reported local antiandrogen activity, regrowth signals, and limited systemic effect. What it was never designed to do is characterise long-term toxicity, carcinogenicity, or endocrine effects of chronic human use. The absence of alarming findings in that literature is mildly reassuring and nothing more.

Sensible risk framing

Compared honestly against the licensed alternative: finasteride's side effects are documented, quantified, and argued about in the open literature. RU-58841's are largely undocumented, which some people misread as "no side effects" and others misread as "hiding something". Both readings are wrong. The accurate statement is that the molecule's local effects are mostly mild and vehicle-driven, its systemic risk is plausibly low by design but unmeasured in humans, and anyone using it is accepting unquantified risk. That is precisely why it remains a research compound, and why we sell it as one: with no treatment claims, and with the one thing we can quantify (what is actually in the bottle) proven per batch on the lab results page.

Shop

RU-58841 5% Solution

Batch 30582 · 55.08 mg/mL assayed · CoA public.

View product →

RU58841 Side Effects: What the Research Actually Shows